Our Strategy

Challenging ideas to drive progress

Our strategy supports our goal to improve the health and quality of life for people affected by the burden of chronic respiratory diseases.

Reaching our goals

Obtain approval of ensifentrine for the maintenance treatment of COPD in the US

A New Drug Application has been submitted to the US FDA for nebulized ensifentrine for the maintenance treatment of COPD. Millions of COPD patients remain symptomatic despite treatment with available therapies. Novel treatments are urgently needed to address this issue. In the US alone, total annual medical costs, indirect and direct, relating to COPD are about $50 billion. We believe ensifentrine will have a significant role helping patients who remain symptomatic on existing treatments for COPD.

Seek strategic relationships

We may seek strategic collaborations with leading biopharmaceutical companies to develop and commercialize ensifentrine. These partnerships could provide significant funding to advance the development of ensifentrine while allowing us to benefit from the development and commercialization expertise of our collaborators.

Pursue development of ensifentrine in additional territories

Initially, we are developing ensifentrine for the US market and seeking strategic partnerships in other regions. We have formed a $219 million strategic collaboration with Nuance Pharma to develop and commercialize ensifentrine in Greater China. The region has an estimated 100 million COPD patients.

Develop additional formulations of ensifentrine

We are developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD via a nebulizer.
In addition to nebulizers, handheld inhalers are frequently used in the treatment of respiratory diseases. Our pipeline includes Dry powder inhaler (DPI) and pressurized metered dose inhaler (pMDI) formulations of ensifentrine, which provide lifecycle and collaboration opportunities.

Advance ensifentrine in additional indications

We believe ensifentrine has potential to be an effective treatment for many respiratory conditions. Our pipeline is focused on indications with unmet medical needs including NCFB, cystic fibrosis and asthma.

Acquire or in-license product candidates for respiratory diseases

We are leveraging our expertise in respiratory diseases to in-license or acquire additional clinical-stage product candidates. We are seeking assets with the potential to become novel treatments for respiratory diseases with significant unmet medical needs.

Company Leadership

Learn more about Verona Pharma’s experienced leadership team.

Company Leadership

Developing novel therapeutics for respiratory diseases

To learn more about Verona Pharma, please get in touch.